Mynewsdesk LinkedIn

The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®.

Affibodys latest Press releases

To the archive

2021-12-02

Notice to attend extraordinary general meeting

The shareholders of Affibody Medical AB (publ) are hereby invited to attend an extraordinary general meeting of the shareholders on Thursday 16 December 2021,...[read more]

2021-12-02

Notice to attend extraordinary general meeting...[read more]

2021-11-16

Affibody enters agreement with ACELYRIN for the development and commercialization of...[read more]

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Research & Development

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies